Adalimumab and anti-adalimumab antibody

Referred to Reference Chemistry Laboratory, St Thomas' Hospital, London SE1 7EH

Alternative names, keywords

Anti-TNF alpha drugs, Humira, Imraldi.

Samples required

Clotted blood (gold cap, 5 mL tube). Smaller tubes are available for paediatric samples.

Trough sample requested (i.e. collected before next infusion)

Interpretation requires full clinical details: drug dosage/ frequency, previous exposure to other biologics, time of sampling, duration of therapy and clinical assessment.

Please use ViaPath/ Biogen forms for Imraldi monitoring.

Test indications

Primary treatment failure (non-response), secondary loss of response, prediction of infusion reactions, adherence to therapy , reintroduction after drug interruption.

Reference range

Adalimumab levels of greater than 6 µg/mL are considered adequate.

Anti-adalimumab antibody: 0 - 10 ng/mL

In the presence of adalimumab, anti-adalimumab antibody may not be detected.

From 23rd September 2019, new assay protocol and platform in use. Results from the new assay are approximately 23% higher. Therapeutic guidance has been updated accordingly. Please use the results from the new protocol as a baseline for future optimisation of therapy.


Turnaround time

Referral lab quotes turnaround time of 2 weeks, however additional time must be allowed for packing, dispatch and delivery of sample, and return and processing of results.


Biochemistry (Referrals)